Buy Comfoderm K cream 0.1% 30 g
  • Buy Comfoderm K cream 0.1% 30 g

Comfoderm K

930 Items
2019-09-19
Dosage form
Brand & Manufacturer
Package Size
$40.00
Quantity
  • done All payments are SSL encrypted
  • done Full Refund if you haven't received your order
  • done International shipping to the USA, UK and Europe

Clinical Pharmacology

The active component of Comfoderm® K, methylprednisolone aceponate, is a non-halogenated synthetic steroid. When applied externally, Comfoderm® K suppresses inflammatory and allergic skin reactions, as well as reactions associated with enhanced proliferation, which leads to a decrease in the objective symptoms of inflammation (erythema, edema, oozing) and subjective sensations (itching, irritation, pain, etc. .). When methylprednisolone aceponate is used externally at the recommended dose, systemic action is minimal in both humans and animals. After repeated application of methylprednisolone aceponon on large surfaces (40-60% of the skin surface), as well as when applied under the occlusive dressing, there are no violations of the adrenal glands: plasma cortisol concentration and its circadian rhythm remain within the normal range, there is no decrease in cortisol in daily urine going on. Methyl prednisolone aceponate (especially its main metabolite, 6α-methylprednisolone-17-propionate) binds to intracellular glucocorticoid receptors. The steroid-receptor complex binds to specific parts of the DNA of the cells of the immune response, thus causing a series of biological effects. In particular, the binding of the steroid-receptor complex with DNA cells of the immune response leads to the induction of macrocortin synthesis. Macrocortin inhibits the release of arachidonic acid and, thereby, the formation of inflammatory mediators such as prostaglandins and leukotrienes. Inhibition of the synthesis of vasodilating prostaglandins by glucocorticoids and the potentiation of the vasoconstrictive action of adrenaline lead to a vasoconstrictor effect.

Suggested use

Topically. Adults and children from 4 months of age. The drug is applied 1 time per day with a thin layer on the affected skin. As a rule, the duration of continuous daily treatment with Komfoderm® K should not exceed 12 weeks for adults and 4 weeks for children. The drug Comfoderm® K is suitable for the treatment of sub-acute and acute inflammatory processes without pronounced soak, while the process is localized on both smooth skin and scalp, including skin prone to fat.

Indications

Inflammatory skin diseases sensitive to treatment with topical glucocorticosteroids: atopic dermatitis, neurodermatitis, children's eczema; true eczema; microbial eczema; simple contact dermatitis; allergic (contact) dermatitis; dishydrotic eczema.

Composition

100 g Methylprednisolone aceponate 0.10 g Excipients: ceramides - 0.5 g, preservative Euxyl PE 9010 (phenoxyethanol 90%, ethylhexylglycerol 10%) in terms of phenoxyethanol - 0.9 mg, isopropyl myristate - 7 g, octyldodecanol - 7 g, hexyl decyl stearate - 7 g, 7 dimethicone, dimethicone, and dimethacone - 7 g, dimethiconedethanol - 7 g; , propylene glycol - 7 g, macrogol 40 stearate - 1.5 g, glyceryl monostearate - 8.5 g, cetostearyl alcohol (cetyl alcohol 60%, stearyl alcohol 40%) - 2 g, disodium edetate - 0.1 g, potassium dihydrogen phosphate - 0.49 g, sodium hydrophosphate dodecahydrate - 0.01 g, purified water - up to 100 g

No customer reviews for the moment.

Write your review

Write your review

Comfoderm K

Dosage and administration

Outwardly. Adults and children from 4 months of age. The drug is applied once a day with a thin layer on the affected skin. As a rule, the duration of continuous daily treatment with Comfoderm® K should not exceed 12 weeks for adults and 4 weeks for children. Comfoderm® K is suitable for the treatment of subacute and acute inflammatory processes without pronounced wetness, with the localization of the process both on smooth skin and on the scalp, including skin prone to oily.

Adverse reactions

The incidence of side effects is classified according to the recommendations of the World Health Organization (WHO): very often (≥ 10%), often (≥ 1%, <10%), infrequently (≥ 0.1%, <1%), rarely ( ≥ 0.01%, <0.1%), very rarely (<0.01%), the frequency is unknown (it is not possible to estimate the frequency of occurrence). Violations of the skin and subcutaneous tissues: rarely perioral dermatitis, skin depigmentation, allergic reactions to the components of the drug; the frequency is unknown atrophy of the skin, telangiectasia, striae, acne-like skin changes (when using the drug for more than 4 weeks and / or on an area of ​​10% or more of the body surface). General disorders and disorders at the injection site: rarely - folliculitis, hypertrichosis; very rarely - itching, burning, erythema, formation of vesicular rash; frequency unknown - systemic effects due to absorption of a glucocorticosteroid (when using the drug for more than 4 weeks and / or on an area of ​​10% or more of the body surface). If any of the side effects indicated in the instructions are aggravated, or any other side effects that are not indicated in the instructions are noted, you should immediately inform your doctor.

Contraindications

Hypersensitivity to the drug; tuberculosis or syphilitic processes in the area of ​​drug application; viral diseases (for example, chicken pox, shingles) in the area of ​​drug application; rosacea, perioral dermatitis in the area of ​​application of the drug; skin areas with reactions to vaccination; children's age up to 4 months.

Special instructions

In the presence of bacterial dermatosis and / or dermatomycosis, in addition to therapy with Komfoderm® K, specific antibacterial or antimycotic treatment is necessary. The drug is not intended for use in ophthalmology. Avoid contact with eyes and mucous membranes. As with the use of systemic corticosteroids, after external use of glucocorticoids, glaucoma may develop (for example, when using the drug in high doses, due to very long use of occlusive dressings or application to the skin around the eyes). Influence on ability to drive motor transport and control mechanisms Not found.

Overdosage

When studying the acute toxicity of methylprednisolone aceponate, there was no risk of acute intoxication in case of excessive single skin use (application of the drug over a large area under conditions favorable for absorption) or in case of unintentional ingestion. Symptoms: at excessively long and / or intensive external application of corticosteroids, atrophy of the skin can develop (thinning of the skin, telangiectasia, striae). Treatment: when signs of skin atrophy appear, the drug should be withdrawn.

  • Brand name: Comfoderm K
  • Active ingredient: Methylprednisolone aceponate, Urea
  • Manufacturer: Sotex

8 other products in the same category:

arrow_upward